Abstracts Archive - Page 963 of 2425 - ACR Meeting Abstracts

Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…
Abstract Number: 131 • 2019 ACR/ARP Annual Meeting
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC. Some have suggested a clinically useful role for aPS-PT as a…
Abstract Number: 132 • 2019 ACR/ARP Annual Meeting
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Alejandro Ibañez-Costa ¹, Ivan Arias de la Rosa ⁴, Maria del Carmen Abalos-Aguilera ¹, Lourdes Alacaide-Ruggiero ⁵, Rafaela Ortega ¹, Nuria Barbarroja ⁶, Eduardo Collantes-Estevez ⁴, Massimo Radin ⁷, Irene Cecchi ⁷, Savino Sciascia ⁸ and Carlos Perez-Sanchez ⁹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with…
Abstract Number: 133 • 2019 ACR/ARP Annual Meeting
Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Tingting Liu¹, Jieyu Gu ¹, Liyan Wan ¹, Gary L. Norman ², Hui Shi ¹ and Chengde Yang ¹, ¹Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²INOVA Diagnostics, Inc., CA 92131
Background/Purpose: Anti-β2GPI-Domain 1 (β2GPI -D1) antibodies are currently considered to be a pathogenic subset of anti-β2GPI antibodies and have been strongly associated with thrombosis and…
Abstract Number: 134 • 2019 ACR/ARP Annual Meeting
‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort
Jieyu Gu¹, Tingting Liu ¹, Liyan Wan ¹, Gary L. Norman ², Chengde Yang ¹ and Hui Shi ³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²INOVA Diagnostics, Inc., CA 92131, ³University of Michigan, Ann Arbor, MI
Background/Purpose: The laboratory criteria used in the 2006 Sydney Classification criteria for antiphospholipid syndrome (APS) which is widely used in clinical practice, includes IgG/IgM isotypes…
Abstract Number: 135 • 2019 ACR/ARP Annual Meeting
Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations
Savino Sciascia¹, Irene Cecchi ², Massimo Radin ², Elena Rubini ², Silvia Grazietta Foddai ², Dario Roccatello ², Chelsea Bentow ³, Andrea Seaman ³, Carlos Ramirez ³ and Michael Mahler ³, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³Inova Diagnostics, San Diego, CA
Background/Purpose: The laboratory diagnostics of antiphospholipid syndrome (APS) takes into account the persistent positivity for anticardiolipin (aCL) and/or anti-β2glycoprotein I (anti-β2GPI) antibodies and/or the presence…
Abstract Number: 136 • 2019 ACR/ARP Annual Meeting
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Savino Sciascia¹, Massimo Radin ², Irene Cecchi ², Maria Laura Bertolaccini ³, Tiziana Bertero ², Elena Rubini ², Antonella Vaccarino ², Mario Bazzan ², Osvaldo Giachino ², Simone Baldovino ², Daniela Rossi ², Giulio Mengozzi ² and Dario Roccatello ², ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom
Background/Purpose: In this study, we sought to perform an unsupervised hierarchical clustering analysis in a large cohort of antiphospholipid antibodies (aPL) positive patients, to identify…
Abstract Number: 137 • 2019 ACR/ARP Annual Meeting
The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Diane Zisa ², Danieli Andrade ³, Vittorio Pengo ⁴, Savino Sciascia ⁵, Maria Tektonidou ⁶, Amaia Ugarte ⁷, Maria Gerosa ⁸, H Michael Belmont ⁹, Rosario Lopez Pedrera ¹⁰, Lanlan Ji ¹¹, Paul Fortin ¹², Maria Efthymiou ¹³, Guilherme De Jesus ¹⁴, David Branch ¹⁵, Laura Andreoli ¹⁶, Michelle Petri ¹⁷, Ricard Cervera ¹⁸, Esther Rodriguez ¹⁹, Jason Knight ²⁰, Tatsuya Atsumi ²¹, Rohan Willis ²², Maria Laura Bertolaccini ²³, Hannah Cohen ¹³, Robert Roubey ²⁴, Doruk Erkan ²⁵, Medha Barbhaiya ² and on Behalf of APS ACTION ²⁶, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, ⁶First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷Hospital Universitario Cruces, University of the Basque Country Autoimmune Diseases Research Unit, Department of Internal M edicine, BioCruces Health, Biscay, Spain, ⁸Istituto Ortopedico Gaetano Pini, University of Milan, Milan, Italy, ⁹NYU Langone Health, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Cordoba, Cordoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹³University College London, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²¹Hokkaido University, Sapporo, Japan, ²²Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, ²³King's College London, London, United Kingdom, ²⁴The University of North Carolina at Chapel Hill, Chapel Hill, NC, ²⁵Hospital for Special Surgery, New York City, ²⁶APS ACTION, New York, NY
Background/Purpose: APS ACTION “Registry” was created to study the long-term natural history and outcomes of persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic…
Abstract Number: 138 • 2019 ACR/ARP Annual Meeting
Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome
Tomás Urrego ¹, Beatriz Frade-Sosa ², Alejandro Hernández ³, Sebastian Ruiz ³, Carolina Rua ⁴, Julieta Duque ⁴, Adriana Vanegas-García ⁵, Carlos H Muñoz-Vahos ⁵, Luis A González ⁵, Gloria Vasquez ⁶ and Jose A Gómez-Puerta², ¹Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Antioquia, Colombia, ²Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Departamento de Medicina Interna, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁴Grupo de Investigación en Trombosis, Medellín, Antioquia, Colombia, ⁵Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁶University of Antioquia, Medellin, Antioquia, Colombia
Background/Purpose: Recurrent thrombosis is an uncommon complication of patients with antiphospholipid syndrome (APS), usually related with persistent high levels of antiphospholipid antibodies (aPL), specially classic aPL…
Abstract Number: 139 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE
Aline Kühl Torricelli¹, Michelle Remião Ugolini-Lopes ¹, Eloisa Bonfa ² and Danieli Andrade ³, ¹Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombophilia that affects young productive individuals with permanent damage and negative impact in quality of life. Recently a…
Abstract Number: 140 • 2019 ACR/ARP Annual Meeting
Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis
Hanxiao You¹, Jiuliang Zhao ², Xinping Tian ², Mengtao Li ³ and Xiaofeng Zeng ², ¹Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic)
Background/Purpose: Portal vein thrombosis (PVT) is a rare and severe clinical phenotype of antiphospholipid syndrome (APS) with a poor prognosis. Anticoagulation therapy is efficient, but is associated with potentially…
Abstract Number: 141 • 2019 ACR/ARP Annual Meeting
Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit
Agna Neto¹, Patrícia Martins ², Mónica Centeno ³, Cláudia Araújo ³, Luísa Pinto ³ and Susana Capela ², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon; Hospital Central do Funchal, Madeira., Lisbon, Portugal, ²Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ³Departamento de Ginecologia, Obstetrícia e Medicina da Reprodução, Hospital de Santa Maria, CHLN, Lisbon, Portugal
Background/Purpose: Women with antiphospholipid syndrome (APS) are at increased risk of recurrent miscarriage, fetal death, placental insufficiency, preeclampsia and fetal growth restriction (FGR). Although treatment…
Abstract Number: 142 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities
Silvia Grazietta Foddai¹, Massimo Radin ¹, Elena Rubini ¹, Irene Cecchi ¹, Savino Sciascia ², Dario Roccatello ¹, Elisa Menegatti ¹, Silvia Gaito ¹, Luca Marozio ¹, Tilde Manetta ¹ and Giulio Mengozzi ¹, ¹University of Turin, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: While current guidelines help defining correct pregnancy standard of care for patients with systemic lupus erythematosus andantiphospholipid syndrome (APS),little is known about the significance…
Abstract Number: 143 • 2019 ACR/ARP Annual Meeting
Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients
Ji-Soong Kim¹, Ga Young Ahn ², Jeongim Choi ³, Jiyoung Lee ⁴, Youngho Park ¹, So-Young Bang ¹ and Sang-Cheol Bae ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Guro Hospital, Korea University College of Medicine, Seoul, ³Busan St. Mary's Medical Center, Busan, ⁴Clinical Research Center for Rheumatoid Arthritis, Seoul
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboembolic and obstetric morbidity associated with antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). This study aims to…
Abstract Number: 144 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype
Shashank Cheemalavagu¹, Beth Wallace ², Wendy Marder ³, Jason Knight ⁴ and Andrew Vreede ⁵, ¹Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine; Rheumatology Section, VA Ann Arbor Health System, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) significantly increases risk of preeclampsia. It is assumed that APS is associated with a subset of severe preeclampsia, HELLP (Hemolysis; Elevated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].